Chemotherapy for Stomach Cancer

This trial explores a special type of chemotherapy called hyperthermic intraperitoneal chemotherapy (HIPEC) for individuals with advanced stomach cancer that has spread to the abdominal area. It combines two drugs, cisplatin and mitomycin C, which are heated and applied directly inside the abdomen to target cancer cells more effectively. Individuals with stomach cancer showing signs of spreading in the abdomen and who have completed 4-6 months of regular chemotherapy might be suitable candidates. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to advancements in cancer treatment.

The trial protocol does not specify whether you need to stop taking your current medications. However, since participants must have completed 4-6 months of systemic therapy before enrolling, it's possible that some medications may need to be adjusted. Please consult with the trial coordinators for specific guidance.

Earlier studies have examined the safety and effectiveness of using cisplatin and mitomycin C in hyperthermic intraperitoneal chemotherapy (HIPEC). Research shows that patients generally tolerate this treatment well, with most managing side effects without major issues. Common side effects include nausea, fatigue, and low blood cell counts, which can usually be managed with standard care.

More detailed information indicates that the safety profile of this treatment remains consistent across different studies. For instance, one study found that patients receiving cisplatin and mitomycin C HIPEC did not experience any unexpected severe side effects, suggesting the treatment is relatively safe for individuals with advanced stomach cancer.

Unlike the standard treatments for stomach cancer, which typically involve systemic chemotherapy, this investigational treatment utilizes hyperthermic intraperitoneal chemotherapy (HIPEC). HIPEC delivers chemotherapy directly to the abdominal cavity, allowing for higher concentrations of cisplatin and mitomycin C to target cancer cells more effectively. By heating the chemotherapy solution to 42°C, it enhances drug absorption and distribution within the abdomen. Researchers are excited about this technique because it aims to maximize the impact on cancer cells while potentially reducing the systemic side effects commonly seen with traditional chemotherapy.

This trial will evaluate hyperthermic intraperitoneal chemotherapy (HIPEC) for stomach cancer. Studies have shown that combining cisplatin and mitomycin C in HIPEC may extend the lives of patients with stomach cancer that has spread to the abdomen. Research indicates that this treatment can prolong life, with one study showing an average survival time of 16.4 months. Another study found that HIPEC increases the chances of surviving for 3 and 5 years compared to surgery alone. Additionally, this treatment can help delay cancer progression. These findings suggest that cisplatin and mitomycin C HIPEC could be a promising option for treating stomach cancer that has spread to the abdomen.²⁵⁶⁷⁸